Shopping Cart
- Remove All
- Your shopping cart is currently empty
Irtemazole (R 60844) is a novel uricosuric substance that is valuable in the treatment of hyperuricemia and gout.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | 106 € | In Stock | |
5 mg | 247 € | In Stock | |
10 mg | 370 € | In Stock | |
25 mg | 620 € | In Stock | |
50 mg | 881 € | In Stock | |
100 mg | 1.197 € | In Stock | |
500 mg | 2.403 € | In Stock |
Description | Irtemazole (R 60844) is a novel uricosuric substance that is valuable in the treatment of hyperuricemia and gout. |
In vivo | Irtemazole (12.5 to 50 mg; oral; 6 patients) caused a maximal decrease in plasma uric acid (after 8 to 12 h) of 46.5%. The uricosuric effect began during the first 60 min after drug administration and it lasted for 7 to 24 h. Renal uric acid excretion returned to its base line value after 8 to 16 h and uric acid clearance after 10.0 to 12.0 h. Doses of irtemazole between 12.5 and 37.5 mg produced a dose-related rise in the uricosuric effect. There was no essential difference between the uricosuric effect of 37.5 mg and 50 mg irtemazole. The D50 dose (that producing a half-maximal effect) was between 16.3 mg and 34.2 mg, (average 24.7 mg). The value of irtemazole in the management of hyperuricaemia and gout remains to be determined.[2] |
Alias | R-60844, R60844, R 60844 |
Molecular Weight | 288.35 |
Formula | C18H16N4 |
Cas No. | 129369-64-8 |
Smiles | C(C=1C=C2C(=CC1)N=C(C)N2)(N3C=CN=C3)C4=CC=CC=C4 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 55 mg/mL (190.74 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.